Cocrystal Pharma, Inc. COCP
We take great care to ensure that the data presented and summarized in this overview for Cocrystal Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in COCP
Top Purchases
Top Sells
About COCP
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Insider Transactions at COCP
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 09
2024
|
Fred Hassan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,067
+0.78%
|
-
|
Oct 09
2024
|
Anthony J Japour Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,924
+50.0%
|
-
|
Oct 09
2024
|
James Joseph Martin Co-CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+49.65%
|
-
|
Oct 09
2024
|
Richard C Pfenniger Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,067
+41.44%
|
-
|
Oct 09
2024
|
Sam Lee President and Co-CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+34.38%
|
-
|
Oct 09
2024
|
Steven D Rubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,957
+0.71%
|
-
|
Oct 09
2024
|
Phillip Md Et Al Frost Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,100
+50.0%
|
-
|
Oct 09
2024
|
Roger D. Kornberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,109
+50.0%
|
-
|
Apr 04
2023
|
Phillip Md Et Al Frost Director |
BUY
Open market or private purchase
|
Indirect |
1,015,229
+43.48%
|
$1,015,229
$1.97 P/Share
|
Aug 20
2021
|
Richard C Pfenniger Jr Director |
BUY
Open market or private purchase
|
Direct |
40,000
+50.0%
|
$40,000
$1.03 P/Share
|
May 04
2021
|
Raymond F Schinazi > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
575,000
-6.97%
|
$1,150,000
$2.95 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 185K shares |
---|